Conditions: Actinic Keratosis
Keywords: Peplin PEP005 Actinic Keratosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: no

Brief summary:
This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: PEP005 (ingenol mebutate) Gel, 0.05% intervention 2: Vehicle Gel
Intervention descriptions: intervention 1: PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days intervention 2: Vehicle Gel once daily for 2 consecutive days

Protocol document: